Epoetin Alfa Market Seen Growing on Anemia Demand, Biosimilars

The Business Research Company says the epoetin alfa market is being lifted by chronic disease prevalence, more drug approvals and expanding biosimilar use. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2035.

Why it matters: - The epoetin alfa market is tied to treatment for anemia linked to chronic kidney disease and chemotherapy, so demand tracks broader chronic disease trends. - Growth in biosimilars, homecare delivery and anemia screening could reshape how patients access injectable anemia treatment.

What happened: - The Business Research Company published its Global Market Report 2026 on the epoetin alfa market, with forecasts running from 2026 to 2035. - The report says the market expanded in the historical period because of high chronic kidney disease incidence, chemotherapy-induced anemia, recombinant erythropoietin success, hospital-based anemia management and a rising dialysis patient population. - The report says future growth will be supported by biosimilar epoetin products, an aging population, more homecare treatment, better screening and efforts to control healthcare costs. - Epoetin alfa is a recombinant form of erythropoietin that stimulates red blood cell production. - The drug is used primarily to treat anemia in patients with chronic kidney disease or those receiving chemotherapy. - Epoetin alfa is administered by injection and is sold under brand names including Epogen and Procrit.

The details: - The report says the market is moving toward broader biosimilar use in anemia care. - The report points to a shift toward home-based injectable therapies. - The report flags integrated chronic kidney disease management as an emerging trend. - Personalized anemia treatment plans are another forecast-period trend cited in the report. - The report also highlights pressure to optimize biologic therapy costs. - A June 2023 Kidney Research UK report said about 7.2 million people in the UK live with chronic kidney disease, more than 10% of the population. - Kidney Research UK said 3.25 million of those patients are in advanced stages and 3.9 million are in early stages. - Kidney Research UK projected the UK chronic kidney disease population will rise to 7.61 million by 2033. - The American Society of Gene and Cell Therapy said in July 2024 that 76 gene therapy trials launched in the second quarter of 2024, up 25% from the prior quarter.

Between the lines: - The report is using chronic disease burden and treatment innovation as the main lens for future demand. - Biosimilars and homecare adoption could pressure branded biologics by changing where and how anemia care is delivered. - The approval pipeline matters because more authorized therapies can widen treatment access and reinforce confidence in biologic medicines.

What's next: - North America held the largest share of the epoetin alfa market in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period, driven by better healthcare access and rising chronic disease prevalence. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company says the 2026 report also adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated graphics and tables. - More information is available in the full report and a free sample.